Literature DB >> 27007550

Efficacy and Safety of APO866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma: A Phase 2 Clinical Trial.

Simone M Goldinger1, Sharon Gobbi Bischof2, Regina Fink-Puches3, Claus-Detlev Klemke4, Brigitte Dréno5, Martine Bagot6, Reinhard Dummer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27007550     DOI： 10.1001/jamadermatol.2016.0401

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  14 in total

Review 1.  Targeting metabolic vulnerabilities of cancer: Small molecule inhibitors in clinic.

Authors:  Satyendra C Tripathi; Johannes F Fahrmann; Jody V Vykoukal; Jennifer B Dennison; Samir M Hanash
Journal:  Cancer Rep (Hoboken)       Date:  2018-09-23

Review 2.  Targeting metabolic dependencies in pediatric cancer.

Authors:  Sameer H Issaq; Christine M Heske
Journal:  Curr Opin Pediatr       Date:  2020-02       Impact factor: 2.856

Review 3.  Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy.

Authors:  Naveen Singh; S Louise Pay; Snehal B Bhandare; Udhaya Arimpur; Edward A Motea
Journal:  Cancers (Basel)       Date:  2020-04-14       Impact factor: 6.639

Review 4.  Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy.

Authors:  Ubaldina Galli; Giorgia Colombo; Cristina Travelli; Gian Cesare Tron; Armando A Genazzani; Ambra A Grolla
Journal:  Front Pharmacol       Date:  2020-05-12       Impact factor: 5.810

Review 5.  Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy.

Authors:  Christine M Heske
Journal:  Front Oncol       Date:  2020-01-17       Impact factor: 6.244

6.  Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity.

Authors:  Romana R Gerner; Sophie Macheiner; Herbert Tilg; David Nachbaur; Simon Reider; Kerstin Siegmund; Felix Grabherr; Lisa Mayr; Bernhard Texler; Patrizia Moser; Maria Effenberger; Hubert Schwaighofer; Alexander R Moschen; Brigitte Kircher; Herbert Oberacher; Robert Zeiser
Journal:  Leukemia       Date:  2020-01-23       Impact factor: 11.528

7.  Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics.

Authors:  Veerle W Daniels; Jason J Zoeller; Nick van Gastel; Kelley E McQueeney; Salma Parvin; Danielle S Potter; Geoffrey G Fell; Vinícius G Ferreira; Binyam Yilma; Rajat Gupta; Johan Spetz; Patrick D Bhola; Jennifer E Endress; Isaac S Harris; Emanuel Carrilho; Kristopher A Sarosiek; David T Scadden; Joan S Brugge; Anthony Letai
Journal:  Sci Signal       Date:  2021-06-08       Impact factor: 8.192

Review 8.  Advances in NAD-Lowering Agents for Cancer Treatment.

Authors:  Moustafa S Ghanem; Fiammetta Monacelli; Alessio Nencioni
Journal:  Nutrients       Date:  2021-05-14       Impact factor: 5.717

9.  Small Molecule Regulators Targeting NAD+ Biosynthetic Enzymes.

Authors:  Alyson Curry; Dawanna White; Yana Cen
Journal:  Curr Med Chem       Date:  2022       Impact factor: 4.740

Review 10.  NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview.

Authors:  Alvinsyah Adhityo Pramono; Gulam M Rather; Herry Herman; Keri Lestari; Joseph R Bertino
Journal:  Biomolecules       Date:  2020-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.